A5057068178- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Cutaneous lymphoproliferative disorders research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- CAR-T cell therapy research
- Chemotherapy-induced cardiotoxicity and mitigation
- Fungal Infections and Studies
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Polyomavirus and related diseases
- Infective Endocarditis Diagnosis and Management
- Virus-based gene therapy research
- Tracheal and airway disorders
- Blood donation and transfusion practices
- Parasitic Diseases Research and Treatment
- Eosinophilic Disorders and Syndromes
- Complement system in diseases
- Immunodeficiency and Autoimmune Disorders
- Childhood Cancer Survivors' Quality of Life
- Aortic Disease and Treatment Approaches
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Phagocytosis and Immune Regulation
- Cancer Genomics and Diagnostics
Hospital Universitari i Politècnic La Fe
2022-2025
Instituto de Investigación Sanitaria La Fe
2023-2024
Sociedad Española de Trombosis y Hemostasia
2022
Leitat Technological Center
2022
Abstract Background Patients with secondary acute myeloid leukemia who previously received hypomethylating agents for prior neoplasms (HMA‐sAML) face a dismal prognosis. Methods The authors analyze the characteristics, therapeutic approaches, and outcomes of patients HMA‐sAML from Programa Español para el Tratamiento de Hemopatías Malignas (PETHEMA) registry. Results A total 479 were included, mostly myelodysplastic syndrome (84%). Frontline therapy consisted intensive chemotherapy (IC) in...
Introduction: Acute lymphoblastic leukemia (ALL) is a prevalent childhood cancer with high cure rate, but poses significant medical challenge in adults and relapsed patients. Philadelphia-like acute (Ph-like ALL) high-risk subtype, approximately half of cases characterized by CRLF2 overexpression frequent concomitant IKZF1 deletions. Methods: To address the need for efficient, rapid, cost-effective detection alterations, we developed novel RT-qPCR technique combining SYBR Green...
Background: In recent years, numerous recurrently mutated genes have been identified in acute myeloid leukemia (AML), some of which, such as FLT3 and IDH1/2, serve therapeutic targets, offering new treatment options. Rapid mutational analysis is crucial for timely optimal therapy selection. This study aims to develop validate a rapid, cost-effective, sensitive screening method detecting IDH1, IDH2, FLT3-TKD2 mutations using polymerase chain reaction (PCR) high-resolution melting curve (HRM)....
Background: Patients with refractory and relapsed acute myeloid leukemia (R/R AML) face a dismal prognosis. CAR-T therapy has emerged as potential treatment option. This study assesses the available clinical evidence on in R/R AML, focusing safety efficacy outcomes. Methods: We included studies for AML published from June 2014 to January 2025. Data patient disease characteristics, constructs, response rates, post-CAR-T allogeneic HSCT (allo-HSCT), outcomes were analyzed. Results: Twenty-five...
The incidence of cardiac morbimortality in acute myeloid leukemia (AML) is not well known. We aim to estimate the cumulative (CI) events AML patients and identify risk factors for their occurrence. Among 571 newly diagnosed patients, 26 (4.6%) developed fatal events, among 525 treated 19 (3.6%) experienced (CI: 2% at 6 months; 6.7% 9 years). Prior heart disease was associated with development (hazard ratio (HR) = 6.9). CI non-fatal 43.7% months 56.9% years. Age ≥ 65 (HR 2.2), relevant...
Graft-vs-host disease (GVHD) is a frequent cause of morbidity and mortality in allogeneic stem cell transplants. Extracorporeal photopheresis (ECP) one the most accepted second-line treatments, but technical issues ECP children might be prohibitive.Patients under 18 y age with corticodependant or corticorefractory GVHD receiving at our hospital were included this retrospective study. was performed an in-line system (CellExTherakos) 2013-2014 off-line (Spectra Optia) from 2015 onwards....
<title>Abstract</title> Post-transplant cyclophosphamide, sirolimus and mycophenolate mofetil (PTCy/siro/MMF) constitutes an innovative well-tolerated acute graft-versus-host disease (aGVHD) prophylaxis after allogeneic stem cell transplantation (allo-HSCT), but risk factors for aGVHD incidence therapy failure in this setting are scarce. The study prospectively registered all consecutive adult patients with hematologic malignancies who received allo-HSCT using PTCy/siro/MMF at our...
Abstract A new‐onset neurological deficit after calcified aortic valve replacement and an hyperdense image on the computed tomography raised suspicion of stroke unusual etiology.
A 23-year-old woman with hereditary hemorrhagic telangiectasia was found in her bedroom presenting right-side hemiparesis and aphasia. Brain computed tomography angiography (CTA) showed a complete occlusion of left-medium cerebral artery (Panel A) that required mechanical thrombectomy. CTA revealed the typical arteriovenous malformations lungs B) but not brain or liver. bubble contrasted echocardiography ruled out intracardiacal shunts. Furthermore, repletion defects were subsegmentarial...
Emicizumab constitutes a novel and effective prophylaxis for hemophilia A patients with without inhibitors. In this case report, we describe an emicizumab-induced photosensitivity that forced permanent sun-exposure suppression. To the best of our knowledge, side effect had not been communicated until present.
According to current guidelines, in chronic lymphocytic leukemia (CLL), only the TP53 molecular status must be evaluated prior every treatment's initiation. However, additional heterogeneous genetic events are known confer a proliferative advantage tumor clone and associated with progression treatment failure CLL patients. Here, we describe implementation of comprehensive targeted sequencing solution that is suitable for routine clinical practice allows detection most common somatic...
Abstract The incidence of cardiac morbi-mortality in acute myeloid leukemia (AML) is not well known. We aim to estimate the cumulative (CI) events AML patients (pts) and identify risk factors for their occurrence. Among 571 newly diagnosed pts, 26 (4.6%) developed fatal 19 (3.6%) among 525 treated pts (CI: 2% at 6 months; 6.7% 9 years). Prior heart disease was associated with development [Hazard Ratio (HR) = 1.9]. CI non-fatal 43.7% months 56.9% years. Age ≥ 65 (HR 2.2), relevant antecedents...